帕金森氏症深部腦部刺激療法市場：按技術、組件、最終用戶和分銷管道分類－2025-2032年全球預測

預計到 2032 年，巴金森氏症深部腦部刺激市場規模將達到 40.2 億美元，複合年成長率為 15.90%。

本書全面介紹了神經調控、多學科臨床路徑和設備創新的進展如何融合在一起，重新定義帕金森氏症患者的治療。

深部腦部刺激（DBS）已從一項實驗性神經外科技術發展成為帕金森氏症患者的重要治療方法。本文從臨床、技術和系統層面闡述了DBS的當代應用。電極設計、刺激程序設定、影像融合和閉合迴路控制的進步正在改變人們對症狀改善、手術流程和長期設備管理的預期。同時，多學科診療模式正在革新圍手術全期路徑，以最佳化候選患者的篩選、降低併發症發生率並改善術後復健。這些趨勢要求醫院系統和專科診所重新思考人員配備、影像處理設備以及神經調控管治，以維持高品質的治療效果。

隨著新功能和自適應技術的湧現，監管互動和支付方參與變得日益重要。製造商和臨床倡導者必須清楚地展示其價值，超越症狀控制，涵蓋生活品質指標、減輕用藥負擔以及後續醫療資源利用等。供應鏈韌性和設備服務模式也同樣成為營運重點，因為醫療機構正在考慮建立內部電池更換、編程後續追蹤、導線管理等服務能力。因此，現代DBS技術的應用不再僅僅被視為一種外科手術設備，而是一個融合了技術、醫療服務和商業策略的綜合性臨床計畫。

本書對當今DBS實踐中正在發生的臨床通訊協定、設備架構、報銷框架和以患者為中心的結果等方面的變革性轉變進行了策略性、深入的概述。

DBS（腦深部刺激）領域正在經歷一場變革性的轉變，這場變革涵蓋臨床實務、設備設計、健保報銷體係以及病患期望等各個面向。臨床上，對精心篩選的患者早期療育的日益重視，促使轉診途徑的修訂以及運動障礙神經科和功能神經外科醫生之間合作的加強。自適應控制模式和改進的電極結構能夠實現更個人化的刺激方案，進而影響手術標靶的選擇和術後程控策略。這些設備層面的改善正推動臨床醫師採用包含認知、自主神經和生活品質等領域（而非僅是運動評分）的療效評估指標。

同時，健保報銷和衛生技術評估框架也在不斷發展，以納入真實世界證據和長期療效數據。這種轉變要求製造商和醫療系統共同製定證據產生計劃，以證明產品的臨床和經濟價值。供應鏈和生產策略正朝著模組化和區域化方向發展，以降低單一來源中斷的風險，並加快軟體驅動型設備更新的上市速度。遠距程式設計、遠端醫療醫療追蹤和患者報告結果正在加速混合醫療模式的普及。總而言之，這些轉變正在重塑競爭動態，並為臨床、技術和商業相關人員之間的策略合作創造機會。

對美國關稅在2025年對DBS設備供應鏈、組件採購、採購成本和跨境製造的累積影響進行嚴格評估

美國2025年關稅的實施對深部腦部刺激（DBS）生態系統產生了多方面的影響，包括成本結構、採購決策和生產佈局的調整。依賴跨境供應導線、植入式脈衝產生器和輔助組件的製造商面臨投入成本上升的困境，這迫使他們重新評估供應商關係和庫存策略。為此，一些醫療設備製造商加快了供應鏈多元化進程，並探索近岸外包方案以降低貿易政策波動帶來的風險；而另一些製造商則選擇承受短期成本上漲，以維持與醫療系統簽訂的合約價格。

從採購角度來看，醫院和門診手術中心重新評估了設備選擇標準，將整體擁有成本、物流複雜性以及保固和服務安排納入考量。集團採購組織和聯網醫療系統加強了長期服務協議和備件供應的談判，以管控營運風險。監管和海關核准流程也影響了新產品上市的前置作業時間，促使製造商更早規劃應用，並與相關人員進行更積極的溝通。隨著時間的推移，關稅調整凸顯了彈性供應鏈設計、透明的成本模型以及醫療設備供應商和醫療服務提供者之間協作合約的重要性。

精細化的細分洞察解釋了DBS技術、組件、終端用戶設定和通路的差異將如何驅動臨床應用和商業策略。

精細的細分觀點揭示了技術選擇、組件架構、臨床環境和分銷模式如何影響DBS（深部腦部刺激）的普及動態和商業策略。基於技術，市場可分為自適應和傳統兩大類。自適應細分市場可進一步分為運動回饋和神經回饋，二者在程式設計複雜性、追蹤順序和證據產生要求方面有顯著差異。專注於運動回饋的設備往往優先考慮與穿戴式裝置和感測器平台的整合，而神經回饋解決方案則需要更先進的訊號處理和閉合迴路檢驗來證明其臨床可靠性。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

• 具有即時神經回饋的封閉回路型自適應刺激系統的出現
• 擴展定向導線技術，以實現更精準的標靶化和症狀控制
• 整合人工智慧驅動的程式設計演算法，以最佳化患者特異性刺激參數
• 發展微創立體定向手術，提升手術精準度
• 可充電植入式脈衝產生器的廣泛應用減少了更換手術的次數。
• 用於遠端DBS設備監測和非侵入性參數調整的無線遙測技術的進步
• 基於患者表現型和生物標記譜的個人化治療通訊協定的重要性日益凸顯。
• 神經科技公司和學術機構合作，共同研發下一代深部腦部刺激技術。
• 加大對旨在緩解非運動症狀的緩解疾病神經調控範式的投資
• 新型電極設計獲得監管部門核准，實現多觸點電流控制功能

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 按技術分類的巴金森氏症深部腦部刺激療法市場

• 自適應
  • 運動回饋
  • 神經回饋
• 傳統的

9. 帕金森氏症深部腦部刺激療法市場（按組件分類）

• 擴張
• 植入式脈衝產生器
• 帶領
• 程式設計師

第10章 帕金森氏症深部腦部刺激療法市場（依最終用戶分類）

• 門診手術中心
• 醫院
• 專科診所

第11章 帕金森氏症深部腦部刺激療法市場（依分銷管道分類）

• 直銷
• 經銷合作夥伴網路

12. 各地區帕金森氏症深部腦部刺激療法市場

• 美洲
  • 北美洲
  • 拉丁美洲
• 歐洲、中東和非洲
  • 歐洲
  • 中東
  • 非洲
• 亞太地區

第13章 帕金森氏症深部腦部刺激療法市場（以群體分類）

• ASEAN
• GCC
• EU
• BRICS
• G7
• NATO

14. 各國帕金森氏症深部腦部刺激療法市場

• 美國
• 加拿大
• 墨西哥
• 巴西
• 英國
• 德國
• 法國
• 俄羅斯
• 義大利
• 西班牙
• 中國
• 印度
• 日本
• 澳洲
• 韓國

第15章 競爭格局

• 2024年市佔率分析
• FPNV定位矩陣，2024
• 競爭分析
  • Medtronic plc
  • Boston Scientific Corporation
  • Abbott Laboratories
  • Neurology Solutions
  • Suzhou PINS Medical Co., Ltd.
  • Aleva Neurotherapeutics SA
  • Renishaw plc
  • Newronika Srl
  • LivaNova, plc
  • Inomed Medizintechnik GmbH

The Deep Brain Stimulation in Parkinson's Disease Market is projected to grow by USD 4.02 billion at a CAGR of 15.90% by 2032.

A comprehensive introduction establishing how advances in neuromodulation, multidisciplinary clinical pathways, and device innovation converge to redefine Parkinson's disease patient care

Deep brain stimulation has evolved from an experimental neurosurgical technique into a cornerstone intervention for selected patients with Parkinson's disease, and this introduction frames the contemporary clinical, technological, and system-level context in which DBS operates. Advances in electrode design, stimulation programming, imaging integration, and closed-loop control have altered expectations around symptomatic benefit, procedural workflows, and long-term device management. At the same time, multidisciplinary care models are shifting perioperative pathways to improve candidate selection, reduce complication rates, and optimize postoperative rehabilitation. These trends require hospital systems and specialty clinics to rethink staffing, imaging capacity, and neuromodulation governance to sustain high-quality outcomes.

Regulatory interaction and payer engagement are increasingly important as novel features and adaptive technologies emerge; manufacturers and clinical champions must now articulate value beyond symptom control to include quality-of-life metrics, reductions in medication burden, and downstream healthcare utilization. Supply chain resilience and device servicing models have likewise become operational priorities as institutions weigh in-house capabilities for battery replacements, programming follow-ups, and lead management. As a result, the contemporary introduction positions DBS not merely as a surgical device but as an integrated clinical program that intersects technology, care delivery, and commercial strategy.

An in-depth strategic overview of transformative shifts in clinical protocols, device architecture, reimbursement frameworks, and patient-centered outcomes shaping DBS practice today

The DBS landscape is undergoing transformative shifts that span clinical practice, device engineering, reimbursement ecosystems, and patient expectations. Clinically, greater emphasis on earlier intervention for well-selected patients is prompting revised referral pathways and heightened collaboration between movement disorder neurologists and functional neurosurgeons. Technological innovation has reinforced this shift: adaptive control paradigms and improved lead architectures are enabling more personalized stimulation profiles, which in turn influence surgical targeting and postoperative programming strategies. These device-level improvements are prompting clinicians to adopt outcome measures that extend beyond motor scores to incorporate cognitive, autonomic, and quality-of-life domains.

Concurrently, reimbursement and health technology assessment frameworks are evolving to accommodate real-world evidence and long-term outcome data. This change encourages manufacturers and health systems to co-develop evidence generation plans that demonstrate clinical and economic value. Supply chain and manufacturing strategies have shifted toward modularity and regionalization to reduce exposure to single-source disruptions and to accelerate time-to-market for software-enabled device updates. Patient expectations and digital engagement are also reshaping post-implant care: remote programming, telehealth follow-ups, and patient-reported outcome capture are accelerating adoption of hybrid care models. Collectively, these shifts are restructuring competitive dynamics and creating opportunities for strategic collaboration across clinical, technical, and commercial stakeholders.

A rigorous assessment of the cumulative impact of United States tariffs in 2025 on supply chains, component sourcing, procurement costs, and cross-border manufacturing for DBS devices

The introduction of tariffs in the United States in 2025 has exerted a multifaceted influence on the deep brain stimulation ecosystem, affecting cost structures, sourcing decisions, and the configuration of manufacturing footprints. Manufacturers reliant on cross-border supply of leads, implantable pulse generators, and ancillary components confronted increased input costs that necessitated reassessment of supplier relationships and inventory strategies. In response, some device producers accelerated diversification of their supply base and explored nearshoring options to mitigate exposure to trade policy volatility, while others absorbed short-term cost increases to sustain contractual pricing with health systems.

From a procurement perspective, hospitals and ambulatory surgical centers revisited device selection criteria to account for total cost of ownership, logistics complexity, and warranty or servicing arrangements. Group purchasing organizations and networked health systems intensified negotiations around long-term service contracts and spare-parts provisioning to manage operational risk. Regulatory and customs processing timelines also influenced lead times for new product introductions, prompting manufacturers to plan earlier submissions and engage in more proactive stakeholder communication. Over time, the tariff-driven adjustments reinforced the importance of resilient supply chain design, transparent cost modeling, and collaborative contracting between device suppliers and care providers.

A granular segmentation insight explaining how distinctions across technology, componentry, end-user settings, and distribution channels drive clinical adoption and commercial strategy in DBS

A granular segmentation perspective clarifies how technology choices, component architectures, clinical settings, and distribution models influence adoption dynamics and commercial strategy for DBS. Based on Technology, market is studied across Adaptive and Conventional. The Adaptive is further studied across Motion Feedback and Neural Feedback, which materially alters programming complexity, follow-up cadence, and evidence-generation requirements. Devices emphasizing motion feedback tend to prioritize integration with wearable and sensor platforms, whereas neural feedback solutions require more sophisticated signal processing and closed-loop validation to demonstrate clinical reliability.

Based on Component, market is studied across Extension, Implantable Pulse Generator, Lead, and Programmer, and each element carries distinct service, replacement, and regulatory considerations. Lead design evolution primarily influences targeting precision and chronic stability, while IPG advancements impact battery life, software capability, and remote-management features. Based on End User, market is studied across Ambulatory Surgical Centers, Hospitals, and Specialty Clinics, which differ in procedural volume, perioperative resources, and post-implant care pathways; high-volume tertiary centers often become centers of excellence that drive referral patterns, whereas specialty clinics may lead in long-term programming and follow-up. Based on Distribution Channel, market is studied across Direct Sales and Distribution Partner Networks, and these choices affect local clinical training, aftermarket service capability, and the speed of new technology adoption. Taken together, these segmentation lenses inform targeted go-to-market design, clinical evidence plans, and service delivery models that stakeholders should align with their strategic priorities.

A regionally focused analysis highlighting divergent regulatory environments, clinical adoption pathways, reimbursement landscapes, and competitive dynamics across major global markets

Regional dynamics create materially different pathways for clinical adoption, regulatory engagement, and commercial strategy across the global landscape. In the Americas, health systems increasingly focus on integrated care pathways, bundled procurement, and performance-based contracting; these priorities favor vendors that can demonstrate robust clinical governance support and predictable service models. Europe, Middle East & Africa present a heterogeneous regulatory and reimbursement environment, where country-level health technology assessment frameworks and procurement customs require localized evidence strategies and flexible commercial arrangements. In several markets within this region, public procurement cycles and reimbursement negotiation timelines dictate phased entry plans and partnerships with established local players. Asia-Pacific offers a contrasting mix of rapidly expanding neurosurgical capacity, public and private healthcare investment, and diverse regulatory pathways that reward agile market entry tactics and strategic alliances.

Across these regions, clinical practice patterns, device servicing models, and patient referral behaviors differ, influencing which provider types become early adopters and how post-implant care is organized. Stakeholders must therefore design regional strategies that balance global product consistency with local regulatory adaptation and tailored clinician engagement. This approach reduces launch friction and aligns evidence generation with payer needs in each geography.

A critical company-level evaluation of strategic priorities, R&D investments, partnership models, and go-to-market approaches that define competitive differentiation within the DBS landscape

Company-level strategies in the DBS sector reflect distinct choices about technology focus, partnership orchestration, and evidence development. Some firms have concentrated R&D on adaptive stimulation and closed-loop systems, prioritizing neural signal analytics and longer-term clinical validation to differentiate on clinical responsiveness. Others have invested in modular component systems that simplify upgrades and servicing, enabling incremental product enhancements without full-system replacement. Several companies emphasize integrated service models that combine device sales with training, remote-programming platforms, and structured follow-up pathways to reduce variation in outcomes and strengthen customer relationships.

Partnership plays are also prominent, with collaborations spanning imaging providers, software analytics companies, and rehabilitation service vendors to create end-to-end clinical solutions. Commercial tactics range from direct engagement with tertiary centers to alliances with distribution partners that provide localized clinical education and aftermarket support. Intellectual property strategies and regulatory submissions reflect these choices: companies investing heavily in adaptive algorithms often follow longer, data-rich regulatory pathways, while those emphasizing hardware refinements pursue iterative clearances. Investors and corporate development teams evaluating vendor capabilities should weigh the alignment between product roadmaps, clinical evidence commitments, and the operational demands of scaling across varied healthcare settings.

A prioritized set of actionable recommendations for industry leaders to accelerate clinical adoption, derisk supply chains, influence policy, and build durable commercial advantage in DBS

Industry leaders can pursue a set of pragmatic, prioritized actions to accelerate clinical adoption, strengthen supply resilience, and create durable commercial advantage in DBS. First, align device development and clinical evidence plans around measurable patient-centered outcomes and real-world performance metrics that resonate with payers and health systems. Second, invest in modular service architectures and training programs that reduce variability in implantation and programming, thereby improving consistency of outcomes across centers. Third, reassess supply chain design to incorporate dual sourcing, regional warehousing, and predictable spare-part provisioning that minimize exposure to trade policy shifts and logistical disruptions.

Fourth, cultivate collaborative relationships with centers of excellence, movement disorder neurologists, and rehabilitation providers to co-develop multicenter evidence and to accelerate diffusion of best practices. Fifth, adopt flexible commercial models that include outcome-based contracting, extended warranties, and bundled services to address evolving payer expectations. Finally, prioritize interoperability and software update pathways that allow devices to evolve post-implant with validated firmware and remote programming capabilities. Implementing these recommendations concurrently strengthens clinical credibility, reduces operational risk, and positions organizations to capitalize on emerging opportunities within integrated care ecosystems.

A transparent research methodology statement describing data collection, primary and secondary engagement, triangulation methods, and validation processes underpinning the DBS analysis

The research approach underlying this analysis combined primary and secondary methods, stakeholder engagement, and iterative validation to ensure robust, reproducible conclusions. Primary inputs included structured interviews with clinicians, procurement leaders, and device engineers, which provided qualitative insights into procedural workflows, evidence priorities, and operational constraints. Secondary sources encompassed peer-reviewed clinical literature, regulatory filings, and device technical specifications to contextualize technological trends and safety performance. These data streams were triangulated to reconcile divergent perspectives and to highlight consistent patterns across clinical settings and geographies.

Analytical frameworks focused on capability mapping, supply chain vulnerability assessment, and clinical pathway integration. Validation cycles involved peer review by independent clinicians and industry experts to test the plausibility of inferred strategic implications. Where appropriate, scenario analysis was used to examine the consequences of policy shifts, technological milestones, or supply interruptions. Overall, the methodology emphasized transparency, reproducibility, and stakeholder relevance, ensuring that the insights are actionable for executive leaders, clinical program directors, and commercial teams seeking to navigate the evolving DBS landscape.

A concise synthesis of strategic takeaways, residual risks, innovation levers, and next-step considerations for stakeholders shaping the future trajectory of DBS in Parkinson's care

The conclusion synthesizes the strategic implications of technological innovation, shifting clinical practice, and evolving commercial dynamics for stakeholders engaged in deep brain stimulation. Advances in adaptive stimulation and closed-loop paradigms are setting new benchmarks for individualized therapy, but they also raise expectations for evidence generation, clinician training, and post-market surveillance. Meanwhile, supply chain and policy developments have underscored the necessity of resilient sourcing strategies and responsive commercial models. Therefore, organizations that integrate clinical program development, robust evidence plans, and flexible operational architectures will be best positioned to convert innovation into sustained clinical and commercial value.

Risk management remains central: procedural complexity, reimbursement uncertainty, and regulatory heterogeneity can all delay adoption or constrain market entry if unaddressed. Conversely, well-executed partnerships, targeted regional strategies, and investment in long-term outcome measurement create defensible differentiation. Ultimately, the path forward requires coordinated action across R&D, clinical engagement, supply chain design, and commercial execution to realize the full potential of DBS for patients with Parkinson's disease.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Emergence of closed-loop adaptive stimulation systems with real-time neural feedback
• 5.2. Expansion of directional lead technology for more precise targeting and symptom control
• 5.3. Integration of AI-driven programming algorithms to optimize patient-specific stimulation parameters
• 5.4. Development of minimally invasive stereotactic approaches with improved surgical accuracy
• 5.5. Growing adoption of rechargeable implantable pulse generators to reduce replacement surgeries
• 5.6. Advances in wireless telemetry for remote DBS device monitoring and noninvasive parameter adjustment
• 5.7. Increasing emphasis on personalized therapy protocols based on patient phenotype and biomarker profiles
• 5.8. Collaboration between neurotechnology companies and academic institutions for next-generation DBS research
• 5.9. Rising investments in disease-modifying neuromodulation paradigms targeting non-motor symptom relief
• 5.10. Regulatory approvals of novel electrode designs enabling multi-contact current steering capabilities

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Deep Brain Stimulation in Parkinson's Disease Market, by Technology

• 8.1. Adaptive
  • 8.1.1. Motion Feedback
  • 8.1.2. Neural Feedback
• 8.2. Conventional

9. Deep Brain Stimulation in Parkinson's Disease Market, by Component

• 9.1. Extension
• 9.2. Implantable Pulse Generator
• 9.3. Lead
• 9.4. Programmer

10. Deep Brain Stimulation in Parkinson's Disease Market, by End User

• 10.1. Ambulatory Surgical Centers
• 10.2. Hospitals
• 10.3. Specialty Clinics

11. Deep Brain Stimulation in Parkinson's Disease Market, by Distribution Channel

• 11.1. Direct Sales
• 11.2. Distribution Partner Networks

12. Deep Brain Stimulation in Parkinson's Disease Market, by Region

• 12.1. Americas
  • 12.1.1. North America
  • 12.1.2. Latin America
• 12.2. Europe, Middle East & Africa
  • 12.2.1. Europe
  • 12.2.2. Middle East
  • 12.2.3. Africa
• 12.3. Asia-Pacific

13. Deep Brain Stimulation in Parkinson's Disease Market, by Group

• 13.1. ASEAN
• 13.2. GCC
• 13.3. European Union
• 13.4. BRICS
• 13.5. G7
• 13.6. NATO

14. Deep Brain Stimulation in Parkinson's Disease Market, by Country

• 14.1. United States
• 14.2. Canada
• 14.3. Mexico
• 14.4. Brazil
• 14.5. United Kingdom
• 14.6. Germany
• 14.7. France
• 14.8. Russia
• 14.9. Italy
• 14.10. Spain
• 14.11. China
• 14.12. India
• 14.13. Japan
• 14.14. Australia
• 14.15. South Korea

15. Competitive Landscape

• 15.1. Market Share Analysis, 2024
• 15.2. FPNV Positioning Matrix, 2024
• 15.3. Competitive Analysis
  • 15.3.1. Medtronic plc
  • 15.3.2. Boston Scientific Corporation
  • 15.3.3. Abbott Laboratories
  • 15.3.4. Neurology Solutions
  • 15.3.5. Suzhou PINS Medical Co., Ltd.
  • 15.3.6. Aleva Neurotherapeutics SA
  • 15.3.7. Renishaw plc
  • 15.3.8. Newronika S.r.l.
  • 15.3.9. LivaNova, plc
  • 15.3.10. Inomed Medizintechnik GmbH

LIST OF FIGURES

• FIGURE 1. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, 2018-2032 (USD MILLION)
• FIGURE 2. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
• FIGURE 3. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 4. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY COMPONENT, 2024 VS 2032 (%)
• FIGURE 5. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY COMPONENT, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 6. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY END USER, 2024 VS 2032 (%)
• FIGURE 7. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 8. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
• FIGURE 9. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 10. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 11. AMERICAS DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 12. NORTH AMERICA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 13. LATIN AMERICA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 14. EUROPE, MIDDLE EAST & AFRICA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 15. EUROPE DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 16. MIDDLE EAST DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 17. AFRICA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 18. ASIA-PACIFIC DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 19. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 20. ASEAN DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 21. GCC DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 22. EUROPEAN UNION DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 23. BRICS DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 24. G7 DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 25. NATO DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 26. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 27. DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SHARE, BY KEY PLAYER, 2024
• FIGURE 28. DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

• TABLE 1. DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
• TABLE 3. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, 2018-2024 (USD MILLION)
• TABLE 4. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, 2025-2032 (USD MILLION)
• TABLE 5. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 6. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 7. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY ADAPTIVE, 2018-2024 (USD MILLION)
• TABLE 8. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY ADAPTIVE, 2025-2032 (USD MILLION)
• TABLE 9. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY ADAPTIVE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 10. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY ADAPTIVE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 11. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY ADAPTIVE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 12. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY ADAPTIVE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 13. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY ADAPTIVE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 14. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY ADAPTIVE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 15. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY MOTION FEEDBACK, BY REGION, 2018-2024 (USD MILLION)
• TABLE 16. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY MOTION FEEDBACK, BY REGION, 2025-2032 (USD MILLION)
• TABLE 17. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY MOTION FEEDBACK, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 18. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY MOTION FEEDBACK, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 19. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY MOTION FEEDBACK, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 20. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY MOTION FEEDBACK, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 21. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY NEURAL FEEDBACK, BY REGION, 2018-2024 (USD MILLION)
• TABLE 22. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY NEURAL FEEDBACK, BY REGION, 2025-2032 (USD MILLION)
• TABLE 23. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY NEURAL FEEDBACK, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 24. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY NEURAL FEEDBACK, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 25. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY NEURAL FEEDBACK, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 26. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY NEURAL FEEDBACK, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 27. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY CONVENTIONAL, BY REGION, 2018-2024 (USD MILLION)
• TABLE 28. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY CONVENTIONAL, BY REGION, 2025-2032 (USD MILLION)
• TABLE 29. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY CONVENTIONAL, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 30. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY CONVENTIONAL, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 31. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY CONVENTIONAL, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 32. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY CONVENTIONAL, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 33. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY COMPONENT, 2018-2024 (USD MILLION)
• TABLE 34. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY COMPONENT, 2025-2032 (USD MILLION)
• TABLE 35. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY EXTENSION, BY REGION, 2018-2024 (USD MILLION)
• TABLE 36. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY EXTENSION, BY REGION, 2025-2032 (USD MILLION)
• TABLE 37. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY EXTENSION, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 38. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY EXTENSION, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 39. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY EXTENSION, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 40. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY EXTENSION, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 41. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY IMPLANTABLE PULSE GENERATOR, BY REGION, 2018-2024 (USD MILLION)
• TABLE 42. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY IMPLANTABLE PULSE GENERATOR, BY REGION, 2025-2032 (USD MILLION)
• TABLE 43. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY IMPLANTABLE PULSE GENERATOR, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 44. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY IMPLANTABLE PULSE GENERATOR, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 45. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY IMPLANTABLE PULSE GENERATOR, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 46. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY IMPLANTABLE PULSE GENERATOR, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 47. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY LEAD, BY REGION, 2018-2024 (USD MILLION)
• TABLE 48. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY LEAD, BY REGION, 2025-2032 (USD MILLION)
• TABLE 49. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY LEAD, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 50. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY LEAD, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 51. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY LEAD, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 52. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY LEAD, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 53. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY PROGRAMMER, BY REGION, 2018-2024 (USD MILLION)
• TABLE 54. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY PROGRAMMER, BY REGION, 2025-2032 (USD MILLION)
• TABLE 55. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY PROGRAMMER, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 56. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY PROGRAMMER, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 57. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY PROGRAMMER, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 58. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY PROGRAMMER, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 59. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 60. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 61. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 62. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 63. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 64. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 65. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 66. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 67. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 68. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 69. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 70. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 71. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 72. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 73. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 74. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 75. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 76. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 77. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 78. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 79. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 80. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 81. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY DIRECT SALES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 82. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY DIRECT SALES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 83. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY DIRECT SALES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 84. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY DIRECT SALES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 85. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY DIRECT SALES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 86. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY DIRECT SALES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 87. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY DISTRIBUTION PARTNER NETWORKS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 88. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY DISTRIBUTION PARTNER NETWORKS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 89. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY DISTRIBUTION PARTNER NETWORKS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 90. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY DISTRIBUTION PARTNER NETWORKS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 91. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY DISTRIBUTION PARTNER NETWORKS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 92. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY DISTRIBUTION PARTNER NETWORKS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 93. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 94. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 95. AMERICAS DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
• TABLE 96. AMERICAS DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
• TABLE 97. AMERICAS DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 98. AMERICAS DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 99. AMERICAS DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY ADAPTIVE, 2018-2024 (USD MILLION)
• TABLE 100. AMERICAS DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY ADAPTIVE, 2025-2032 (USD MILLION)
• TABLE 101. AMERICAS DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY COMPONENT, 2018-2024 (USD MILLION)
• TABLE 102. AMERICAS DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY COMPONENT, 2025-2032 (USD MILLION)
• TABLE 103. AMERICAS DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 104. AMERICAS DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 105. AMERICAS DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 106. AMERICAS DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 107. NORTH AMERICA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 108. NORTH AMERICA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 109. NORTH AMERICA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 110. NORTH AMERICA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 111. NORTH AMERICA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY ADAPTIVE, 2018-2024 (USD MILLION)
• TABLE 112. NORTH AMERICA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY ADAPTIVE, 2025-2032 (USD MILLION)
• TABLE 113. NORTH AMERICA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY COMPONENT, 2018-2024 (USD MILLION)
• TABLE 114. NORTH AMERICA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY COMPONENT, 2025-2032 (USD MILLION)
• TABLE 115. NORTH AMERICA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 116. NORTH AMERICA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 117. NORTH AMERICA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 118. NORTH AMERICA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 119. LATIN AMERICA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 120. LATIN AMERICA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 121. LATIN AMERICA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 122. LATIN AMERICA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 123. LATIN AMERICA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY ADAPTIVE, 2018-2024 (USD MILLION)
• TABLE 124. LATIN AMERICA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY ADAPTIVE, 2025-2032 (USD MILLION)
• TABLE 125. LATIN AMERICA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY COMPONENT, 2018-2024 (USD MILLION)
• TABLE 126. LATIN AMERICA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY COMPONENT, 2025-2032 (USD MILLION)
• TABLE 127. LATIN AMERICA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 128. LATIN AMERICA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 129. LATIN AMERICA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 130. LATIN AMERICA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 131. EUROPE, MIDDLE EAST & AFRICA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
• TABLE 132. EUROPE, MIDDLE EAST & AFRICA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
• TABLE 133. EUROPE, MIDDLE EAST & AFRICA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 134. EUROPE, MIDDLE EAST & AFRICA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 135. EUROPE, MIDDLE EAST & AFRICA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY ADAPTIVE, 2018-2024 (USD MILLION)
• TABLE 136. EUROPE, MIDDLE EAST & AFRICA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY ADAPTIVE, 2025-2032 (USD MILLION)
• TABLE 137. EUROPE, MIDDLE EAST & AFRICA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY COMPONENT, 2018-2024 (USD MILLION)
• TABLE 138. EUROPE, MIDDLE EAST & AFRICA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY COMPONENT, 2025-2032 (USD MILLION)
• TABLE 139. EUROPE, MIDDLE EAST & AFRICA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 140. EUROPE, MIDDLE EAST & AFRICA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 141. EUROPE, MIDDLE EAST & AFRICA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 142. EUROPE, MIDDLE EAST & AFRICA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 143. EUROPE DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 144. EUROPE DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 145. EUROPE DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 146. EUROPE DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 147. EUROPE DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY ADAPTIVE, 2018-2024 (USD MILLION)
• TABLE 148. EUROPE DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY ADAPTIVE, 2025-2032 (USD MILLION)
• TABLE 149. EUROPE DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY COMPONENT, 2018-2024 (USD MILLION)
• TABLE 150. EUROPE DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY COMPONENT, 2025-2032 (USD MILLION)
• TABLE 151. EUROPE DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 152. EUROPE DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 153. EUROPE DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 154. EUROPE DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 155. MIDDLE EAST DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 156. MIDDLE EAST DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 157. MIDDLE EAST DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 158. MIDDLE EAST DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 159. MIDDLE EAST DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY ADAPTIVE, 2018-2024 (USD MILLION)
• TABLE 160. MIDDLE EAST DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY ADAPTIVE, 2025-2032 (USD MILLION)
• TABLE 161. MIDDLE EAST DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY COMPONENT, 2018-2024 (USD MILLION)
• TABLE 162. MIDDLE EAST DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY COMPONENT, 2025-2032 (USD MILLION)
• TABLE 163. MIDDLE EAST DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 164. MIDDLE EAST DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 165. MIDDLE EAST DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 166. MIDDLE EAST DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 167. AFRICA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 168. AFRICA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 169. AFRICA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 170. AFRICA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 171. AFRICA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY ADAPTIVE, 2018-2024 (USD MILLION)
• TABLE 172. AFRICA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY ADAPTIVE, 2025-2032 (USD MILLION)
• TABLE 173. AFRICA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY COMPONENT, 2018-2024 (USD MILLION)
• TABLE 174. AFRICA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY COMPONENT, 2025-2032 (USD MILLION)
• TABLE 175. AFRICA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 176. AFRICA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 177. AFRICA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 178. AFRICA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 179. ASIA-PACIFIC DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 180. ASIA-PACIFIC DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 181. ASIA-PACIFIC DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 182. ASIA-PACIFIC DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 183. ASIA-PACIFIC DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY ADAPTIVE, 2018-2024 (USD MILLION)
• TABLE 184. ASIA-PACIFIC DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY ADAPTIVE, 2025-2032 (USD MILLION)
• TABLE 185. ASIA-PACIFIC DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY COMPONENT, 2018-2024 (USD MILLION)
• TABLE 186. ASIA-PACIFIC DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY COMPONENT, 2025-2032 (USD MILLION)
• TABLE 187. ASIA-PACIFIC DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 188. ASIA-PACIFIC DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 189. ASIA-PACIFIC DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 190. ASIA-PACIFIC DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 191. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 192. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 193. ASEAN DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 194. ASEAN DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 195. ASEAN DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 196. ASEAN DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 197. ASEAN DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY ADAPTIVE, 2018-2024 (USD MILLION)
• TABLE 198. ASEAN DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY ADAPTIVE, 2025-2032 (USD MILLION)
• TABLE 199. ASEAN DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY COMPONENT, 2018-2024 (USD MILLION)
• TABLE 200. ASEAN DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY COMPONENT, 2025-2032 (USD MILLION)
• TABLE 201. ASEAN DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 202. ASEAN DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 203. ASEAN DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 204. ASEAN DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 205. GCC DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 206. GCC DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 207. GCC DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 208. GCC DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 209. GCC DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY ADAPTIVE, 2018-2024 (USD MILLION)
• TABLE 210. GCC DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY ADAPTIVE, 2025-2032 (USD MILLION)
• TABLE 211. GCC DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY COMPONENT, 2018-2024 (USD MILLION)
• TABLE 212. GCC DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY COMPONENT, 2025-2032 (USD MILLION)
• TABLE 213. GCC DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 214. GCC DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 215. GCC DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 216. GCC DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 217. EUROPEAN UNION DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 218. EUROPEAN UNION DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 219. EUROPEAN UNION DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 220. EUROPEAN UNION DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 221. EUROPEAN UNION DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY ADAPTIVE, 2018-2024 (USD MILLION)
• TABLE 222. EUROPEAN UNION DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY ADAPTIVE, 2025-2032 (USD MILLION)
• TABLE 223. EUROPEAN UNION DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY COMPONENT, 2018-2024 (USD MILLION)
• TABLE 224. EUROPEAN UNION DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY COMPONENT, 2025-2032 (USD MILLION)
• TABLE 225. EUROPEAN UNION DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 226. EUROPEAN UNION DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 227. EUROPEAN UNION DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 228. EUROPEAN UNION DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 229. BRICS DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 230. BRICS DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 231. BRICS DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 232. BRICS DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 233. BRICS DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY ADAPTIVE, 2018-2024 (USD MILLION)
• TABLE 234. BRICS DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY ADAPTIVE, 2025-2032 (USD MILLION)
• TABLE 235. BRICS DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY COMPONENT, 2018-2024 (USD MILLION)
• TABLE 236. BRICS DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY COMPONENT, 2025-2032 (USD MILLION)
• TABLE 237. BRICS DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 238. BRICS DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 239. BRICS DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 240. BRICS DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 241. G7 DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 242. G7 DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 243. G7 DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 244. G7 DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 245. G7 DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY ADAPTIVE, 2018-2024 (USD MILLION)
• TABLE 246. G7 DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY ADAPTIVE, 2025-2032 (USD MILLION)
• TABLE 247. G7 DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY COMPONENT, 2018-2024 (USD MILLION)
• TABLE 248. G7 DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY COMPONENT, 2025-2032 (USD MILLION)
• TABLE 249. G7 DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 250. G7 DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 251. G7 DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 252. G7 DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 253. NATO DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 254. NATO DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 255. NATO DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 256. NATO DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 257. NATO DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY ADAPTIVE, 2018-2024 (USD MILLION)
• TABLE 258. NATO DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY ADAPTIVE, 2025-2032 (USD MILLION)
• TABLE 259. NATO DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY COMPONENT, 2018-2024 (USD MILLION)
• TABLE 260. NATO DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY COMPONENT, 2025-2032 (USD MILLION)
• TABLE 261. NATO DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 262. NATO DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 263. NATO DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 264. NATO DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 265. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 266. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 267. UNITED STATES DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 268. UNITED STATES DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 269. UNITED STATES DEEP BRAIN STIMULAT